NasdaqCM:OVIDBiotechs
Ovid Therapeutics (OVID) Q4 Profit Challenges Ongoing Loss Narrative
Ovid Therapeutics (OVID) closed FY 2025 with fourth quarter revenue of US$0.72 million and basic EPS of US$0.12, alongside trailing twelve month revenue of US$7.25 million and a trailing basic EPS loss of US$0.24. Over the past year, the company has seen quarterly revenue move from US$0.08 million in Q4 2024 to US$6.27 million in Q2 2025 and US$0.72 million in Q4 2025. Basic EPS has ranged from a loss of US$0.20 in Q3 2024 to a loss of US$0.17 in Q3 2025 and a profit of US$0.12 in Q4 2025...